| Literature DB >> 32346024 |
Rajini Nagrani1, Ronja Foraita2, Francesco Gianfagna3,4, Licia Iacoviello5, Staffan Marild6, Nathalie Michels7, Dénes Molnár8, Luis Moreno9, Paola Russo10, Toomas Veidebaum11, Wolfgang Ahrens2,12, Manuela Marron2.
Abstract
As the prevalence of metabolic syndrome (MetS) in children and young adults is increasing, a better understanding of genetics that underlie MetS will provide critical insights into the origin of the disease. We examined associations of common genetic variants and repeated MetS score from early childhood to adolescence in a pan-European, prospective IDEFICS/I.Family cohort study with baseline survey and follow-up examinations after two and six years. We tested associations in 3067 children using a linear mixed model and confirmed the results with meta-analysis of identified SNPs. With a stringent Bonferroni adjustment for multiple comparisons we obtained significant associations(p < 1.4 × 10-4) for 5 SNPs, which were in high LD (r2 > 0.85) in the 16q12.2 non-coding intronic chromosomal region of FTO gene with strongest association observed for rs8050136 (effect size(β) = 0.31, pWald = 1.52 × 10-5). We also observed a strong association of rs708272 in CETP with increased HDL (p = 5.63 × 10-40) and decreased TRG (p = 9.60 × 10-5) levels. These findings along with meta-analysis advance etiologic understanding of childhood MetS, highlighting that genetic predisposition to MetS is largely driven by genes of obesity and lipid metabolism. Inclusion of the associated genetic variants in polygenic scores for MetS may prove to be fundamental for identifying children and subsequently adults of the high-risk group to allow earlier targeted interventions.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32346024 PMCID: PMC7188794 DOI: 10.1038/s41598-020-64031-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flowchart for inclusion/exclusion criteria.
Study characteristics at baseline.
| Characteristics | Mean (±SD)/n (%)N = 3067 | |
|---|---|---|
| Girls | 1535 (50.05) | |
| No. of children | T0 | 2987 (35.05) |
| T1 | 2907 (34.12) | |
| T3 | 2627 (30.83) | |
| New children enrolled at T1 | 80 (2.61) | |
| Age (years) | 6.20 (±1.77) | |
| Study Region | Italy | 644 (21.00) |
| Estonia | 299 (9.75) | |
| Belgium | 214 (6.98) | |
| Sweden | 434 (14.15) | |
| Germany | 634 (20.67) | |
| Hungary | 461 (15.03) | |
| Spain | 381 (12.42) | |
| BMI categories by Cole | Thinness grade 1–3 | 305 (9.94) |
| Normal weight | 2162 (70.49) | |
| Overweight/obese | 600 (19.56) | |
| SBP (mmHg), n = 2965 | 100.44 (±9.07) | |
| DBP (mmHg), n = 2966 | 63.26 (±6.39) | |
| WC (cm), n = 3010 | 54.44 (±7.03) | |
| HOMA-IR, n = 1946 | 0.92 (±0.74) | |
| TRG (mg/dL), n = 2636 | 57.62 (±25.94) | |
| HDL (mg/dL), n = 2640 | 52.51 (±14.28) | |
| Metabolic Syndrome Score, n = 1845 | 0.21 (±2.65) | |
| Relatedness | 1st degree (sharing ≥ 50% DNA) | 141 (4.59) |
| 2nd degree (sharing < 50 to ≥ 25% DNA) | 188 (6.12) | |
| Distant relation (sharing < 25 to ≥1% DNA) | 2728 (88.94) | |
BMI = body mass index, DBP = diastolic blood pressure, HDL = high density lipoprotein, HOMA-IR = homeostasis model assessment of insulin resistance, SBP = systolic blood pressure, SD = standard deviation, TRG = triglycerides, WC = waist circumference. n stated in case of missingness.
Association of markers with longitudinal Metabolic Syndrome score in children of IDEFICS/I.Family study.
| Locus | Chr | SNP ID | N | Effect allele | EAF | ß | SE | p-value | Multiple correction | |
|---|---|---|---|---|---|---|---|---|---|---|
| FDR | Bonferroni | |||||||||
| 16q12.2 | rs8057044a | 2628 | A | 0.49 | 0.26 | 0.07 | 3.04 × 10−4 | 0.018 | 0.106 | |
| 16q13 | rs708272 | 2752 | A | 0.41 | −0.25 | 0.07 | 4.49 × 10−4 | 0.023 | 0.157 | |
| 16q12.2 | rs8044769 | 2751 | T | 0.46 | −0.24 | 0.07 | 5.91 × 10−4 | 0.026 | 0.207 | |
| 15q21.2 | rs3764220a | 2708 | G | 0.0004 | 5.84 | 1.81 | 1.26 × 10−3 | 0.045 | 0.441 | |
| 16q12.2 | rs17817288a | 2635 | A | 0.48 | −0.23 | 0.07 | 1.41 × 10−3 | 0.045 | 0.496 | |
| 16q12.2 | rs8047395a | 2540 | G | 0.47 | −0.23 | 0.07 | 1.49 × 10−3 | 0.045 | 0.523 | |
| 12q24.11 | rs2075260 | 2749 | G | 0.18 | −0.29 | 0.09 | 1.63 ×10−3 | 0.045 | 0.571 | |
| 4p12 | rs10938397a | 2082 | G | 0.40 | 0.26 | 0.08 | 1.66 × 10−3 | 0.045 | 0.581 | |
ß = estimated coefficient, Chr = chromosome, EAF = effect allele frequency, FDR = false discovery rate, SNP = single nucleotide polymorphism, SE = standard error.
The effect allele is the allele corresponding to the calculated risk. Adjusted for age, sex, country of residence, first five principal components as fixed effects and kinship matrix to define the covariance structure of the random effect. SNPs significant after Bonferroni correction are marked in bold. aimputed SNPs.
Figure 2Regional association plot of markers with longitudinal metabolic syndrome score in children, recombination hotspots, and linkage disequilibrium heatmap for the 16q12.2 locus. −log10 of p values (left y-axis) drawn from the study participants of IDEFICS/I.Family cohort for a 500 kb region covering the entire FTO gene. The purple circle indicates the query variant (rs8050136). The LD estimates are color-coded as a heatmap from dark blue (0 ≥ r2 > 0.2) to red (0.8 ≥ r2 > 1.0). The bottom panel shows the genes and their orientation for each region. We based the association analysis on a one degree of freedom Wald t-test applied on linear mixed model, adjusted for age, sex, country of residence, first five principal components as fixed effects and kinship matrix to define the covariance structure of the random effect. The blue line represents the recombination rate (right y-axis) to estimate putative recombination hotspots across the region from HapMap.
Association of markers with longitudinal Metabolic Syndrome stratified by sex.
| Locus | Chr | SNP ID | Effect allele | Boys | Girls | ||||
|---|---|---|---|---|---|---|---|---|---|
| EAF | ß (SE) | p-value | EAF | ß (SE) | p-value | ||||
| 16q12.2 | rs8050136 | A | 0.42 | 0.33 (0.10) | 0.001 | 0.42 | 0.29 (0.10) | 0.004 | |
| 16q12.2 | rs1121980 | A | 0.44 | 0.37 (0.10) | <0.001 | 0.45 | 0.25 (0.10) | 0.012 | |
| 16q12.2 | rs1558902 | A | 0.43 | 0.32 (0.10) | 0.001 | 0.43 | 0.28 (0.10) | 0.005 | |
| 16q12.2 | rs9939609 | A | 0.42 | 0.30 (0.10) | 0.002 | 0.42 | 0.30 (0.10) | 0.004 | |
| 16q12.2 | rs1421085 | C | 0.43 | 0.32 (0.10) | 0.001 | 0.43 | 0.28 (0.10) | 0.006 | |
| 16q12.2 | rs8057044 | A | 0.49 | 0.33 (0.10) | 0.001 | 0.49 | 0.21 (0.10) | 0.043 | |
| 16q13 | rs708272 | A | 0.41 | −0.32 (0.10) | 0.002 | 0.41 | −0.18 (0.10) | 0.072 | |
| 16q12.2 | rs8044769 | T | 0.46 | −0.24 (0.10) | 0.015 | 0.46 | −0.24 (0.10) | 0.014 | |
| 15q21.2 | rs3764220 | G | 0.0004 | 7.13 (2.42) | 0.003 | 0.0004 | 3.74 (2.79) | 0.180 | |
| FTO | 16q12.2 | rs17817288 | A | 0.48 | −0.29 (0.10) | 0.004 | 0.48 | −0.18 (0.10) | 0.074 |
| FTO | 16q12.2 | rs8047395 | G | 0.46 | −0.35 (0.10) | 0.001 | 0.47 | −0.13 (0.10) | 0.210 |
| 12q24.11 | rs2075260 | G | 0.17 | −0.27 (0.13) | 0.045 | 0.18 | −0.33 (0.13) | 0.010 | |
| 4p12 | rs10938397 | G | 0.39 | 0.27 (0.12) | 0.022 | 0.42 | 0.26 (0.11) | 0.025 | |
ß = estimated coefficient, Chr = chromosome, EAF = effect allele frequency, FDR = false discovery rate, PVAL = p-value, SNP = single nucleotide polymorphism, SE = standard error.
The effect allele is the allele corresponding to the calculated risk. Adjusted for age, sex, country of residence, first five principal components as fixed effects and kinship matrix to define the covariance structure of the random effect. The results here are presented for the markers that reached statistical significance after correction for FDR in the main analysis in Table 2.
Figure 3Flow Diagram of Study Selection Process for Meta-analysis.
Characteristics of studies included in the meta-analysis.
| Author | Sample Size | MetS cases (n) | Controls (n) | Criteria for MetS | Ethnicity/Study Location | Population Type | Study Quality, NOS | |
|---|---|---|---|---|---|---|---|---|
| Ahmad, 2010 | 21674 | 4775 | 16899 | rs8050136 | modified NCEP ATP III | White women | Health professionals from an RCT | 9 |
| Al-Attar, 2008 | 2121 | 474 | 1647 | rs9939609 | IDF, NCEP ATP III | Canadians of multi-ethnic origin | General | 7 |
| Armamento-Villareal, 2016 | 165 | 53 | 112 | rs8050136 | JIS | Caucasians | Obese older adults | 6 |
| Attaoua, 2009b | 119 | 34 | 85 | rs1421085 | NCEP ATP III | Caucasians | Obese women | 7 |
| Attaoua, 2008 | 207 | 75 | 132 | rs1421085 | NCEP ATP III | Caucasians | Patients of PCOS | 6 |
| Baik, 2012 | 4590 | 1487 | 3103 | rs9939609 | AHA/NHLBI | Korean | General | 9 |
| Chedraui, 2016 | 192 | 103 | 89 | rs9939609 | AHA/NHLBI | Ecuador | postmenopausal women | 9 |
| Cheung, 2011 | 1446 | 225 | 1221 | rs8050136 | JIS | Hong Kong | General | 9 |
| Col, 2017a | 100 | 60 | 40 | rs9939609 | NCEP ATP III | Caucasians in Turkey | Obese adolescents | 6 |
| Cruz, 2010 | 936 | 389 | 547 | rs9939609 | AHA/NHLBI | Mexico | Blood donors without a family history of diabetes | 7 |
| de Luis, 2013 | 457 | 186 | 271 | rs9939609 | NCEP ATP III | Caucasians | Obese females | 6 |
| Dusatkova, 2013a | 1443 | 111 | 1332 | rs9939609 | IDF | Czech adolescents | underweight, normal, overweight and obese adolescents | 9 |
| Elouej, 2016 | 685 | 340 | 345 | rs9939609, rs1421085 | IDF | Tunisian | General | 9 |
| Fawwad, 2015 | 296 | 194 | 102 | rs9939609 | IDF, NCEP ATP III | Pakistan | Patients of Type 2 diabetes | 7 |
| Freathy (NBFC1966), 2008 | 4423 | 293 | 4130 | rs9939609 | NCEP ATP III | European | General | 8 |
| Freathy (Oxford Biobank), 2008 | 1149 | 169 | 980 | rs9939609 | NCEP ATP III | European | General | 8 |
| Freathy (Caerphilly), 2008 | 1046 | 216 | 830 | rs9939609 | NCEP ATP III | European | General | 8 |
| Freathy (UKT2D GCC Controls), 2008 | 1858 | 299 | 1559 | rs9939609 | NCEP ATP III | European | General | 8 |
| Freathy (BWHHS), 2008 | 3191 | 1449 | 1742 | rs9939609 | NCEP ATP III | European | General | 8 |
| Freathy (InChianti), 2008 | 888 | 250 | 638 | rs9939609 | NCEP ATP III | European | General | 8 |
| Guclu-Geyik, 2016 | 1967 | 923 | 1044 | rs1421085, rs9939609 | NCEP ATP III | Turkish | General | 9 |
| Hotta, 2011 | 1677 | 1096 | 581 | rs1121980, rs1421085, rs1558902, rs8050136, rs9939609 | study-specific | Japanese | Hospital based | 5 |
| Hu, 2015 | 489 | 245 | 244 | rs1421085, rs9939609 | IDF | Kazakh adults of Xinjiang, china | General | 9 |
| Khella, 2017 | 197 | 92 | 105 | rs9939609 | IDF | Egyptian | Hospital based | 7 |
| Liem, 2010a | 1275 | 886 | 389 | rs9939609 | IDF | Dutch | General | 9 |
| Liguori, 2014 | 1000 | 372 | 628 | rs1121980, rs1421085, rs9939609 | AHA/NHLBI | Italy | morbidly obese | 6 |
| Malgorzata, 2018 | 425 | 162 | 263 | rs9939609 | IDF | Polish | General | 8 |
| Petkeviciene, 2016 | 1020 | 360 | 660 | rs9939609 | IDF | Lithuanian | General | 9 |
| Phillips, 2012 | 1753 | 877 | 876 | rs9939609 | NCEP ATP III | French | General | 9 |
| Ramos, 2015 | 199 | 49 | 150 | rs8050136, rs9939609 | JIS | Caucasians | Patients of PCOS | 6 |
| Ranjith, 2011 | 485 | 295 | 190 | rs9939609 | IDF, NCEP ATP III | Asian Indian | Patients of AMI | 7 |
| Reynolds, 2013 | 179 | 93 | 86 | rs9939609 | IDF | Irish/British Caucasian | Chronically treated patients with Schizophrenia | 6 |
| Rodrigues, 2015 | 146 | 114 | 32 | rs9939609 | AHA/NHLBI | Multiethnic | Bariatric surgery patients | 6 |
| Rotter, 2016 | 272 | 144 | 128 | rs9939609 | IDF | Caucasian | Volunteers from primary health care centres | 6 |
| Sedaghati-khayat, 2018 | 746 | 341 | 405 | rs1121980, rs1421085, rs1558902, rs8050136 | JIS | Iran | General | 7 |
| Sikhayeva, 2017 | 697 | 208 | 489 | rs8050136, rs9939609 | NCEP ATP III | Ethnic Kazakhs | Hospital-based | 9 |
| Sjogren, 2008 | 14996 | 3843 | 11153 | rs9939609 | study-specific | Swedish | General | 8 |
| Ślęzak, 2018 | 191 | 100 | 91 | rs1421085, rs1558902, rs9939609 | NCEP ATP III | Poland | Not given | 5 |
| Steemburgo, 2012 | 236 | 192 | 44 | rs9939609 | JIS | Brazil | Patients of Type 2 diabetes | 7 |
| Tabara, 2009 | 2043 | 333 | 1710 | rs9939609 | modified NCEP ATP III | Japanese | General | 6 |
| Vankova, 2012 | 164 | 16 | 148 | rs9939609 | WHO | Bulgarian | Centrally obese and normal volunteers | 5 |
| Wang, 2010 | 236 | 108 | 128 | rs1421085, rs8050136, rs9939609 | IDF | Han Chinese | Outpatients of endocrinology unit | 6 |
| Zhao, 2014a | 3477 | 431 | 3046 | rs9939609 | modified NCEP ATP III | Chinese | General | 9 |
AMI = acute myocardial infarction; IDF = International Diabetes Federation; JIS = Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society and International Association for the Study of Obesity, 2009; MetS = metabolic syndrome; NCEP ATP II = the National Cholesterol Education Program Adult Treatment Panel III; NOS Newcastle - Ottawa Quality Assessment Scale; PCOS = polycystic ovarian syndrome; RCT = randomized controlled trials. aStudies conducted in the young population (age < 18 years),bsub-sample of the study was utilized. Genotypic frequency from NCEP ATP III was utilized in studies reporting both IDF and NCEP ATP III definitions of MetS.
Figure 4Forest plots of random effect meta-analysis of the association of FTO variants (rs8050136, rs1121980, rs1558902, rs9939609, rs1421085) with Metabolic Syndrome. CI = confidence interval. Sizes of data markers indicate the weight of each study in the analysis. Study-specific odds ratios were pooled using random-effects meta-analysis. Col, 2017; Dusatkova, 2013; Liem 2010; Zhao 2014 were conducted in the young population (age <18 years). Additive ORs were used as indicated in the study for Liem, 2010; Sjogren, 2008; Zhao; 2014.